Exelixis (EXEL)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$69.39+4.82%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put EXEL beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisManagement screens strong on capital allocation, earnings delivery, margins, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskMostly healthy — no soft spokes
Exelixis depends on Cabometyx revenue and zanzalintinib development to sustain its strong recent performance. Revenue grew 10% year over year in both reported first and second quarters. Q3 2026 non-GAAP earnings beat consensus by 19%. EXEL trades at 19× P/E versus a 21× peer median. The price reflects less growth than our forecast. Zanzalintinib launch hurdles and a 28% next-quarter miss probability pose risks. peer multiples imply a price about 20% above where it trades. Our read remains intact; this read is provisional.
Trailing returns as of 2026-10-30. EXEL is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering EXEL (as of Oct 2026).
Based on 9 Wall Street analysts offering 12-month price targets for EXEL in the last 4 months.
Continue this research
Compare EXEL with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| EXEL Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put EXEL next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance zanzalintinib clinical development
PDUFA timing and continued pivotal planning advance zanzalintinib toward potential approval.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $69.39
The last 12 months of price, then the range of analyst 12-month targets from today’s $69.39.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Threatens: Advance zanzalintinib clinical development program
Zanzalintinib launch may face hurdles impacting growth.
3-month delay negatively impacts zanzalintinib development timeline.
Threatens: Advance zanzalintinib clinical development program
FDA review extension delays zanzalintinib development.
Threatens: Advance zanzalintinib clinical development program
FDA review extension impacts zanzalintinib development timeline.
Threatens: Grow cabozantinib franchise revenue
Lower revenue outlook impacts growth of cabozantinib franchise.
Advances: Grow cabozantinib franchise revenue
Strong cabozantinib growth supports revenue objectives.
Threatens: Advance zanzalintinib clinical development program
Lowered revenue guidance impacts zanzalintinib development plans.